TLR9 and neoplasm: Intratumoral SD-101, a synthetic CpG oligonucleotide that stimulates Toll-like receptor 9 (TLR9) and is directly injected into the tumor site, has been shown to increase effectiveness of immune activation at the tumor site when used in combination with PD-1 inhibitors [6].